Jason Park

Jason Park, Ph.D. is an Operating Partner at Flagship Pioneering where he leads a team of entrepreneurial scientists to develop the science, intellectual property, and business strategy that form the foundation of Flagship’s next breakthrough companies. Jason has co-founded Empress Therapeutics, where he served as president and CEO, and Inzen Therapeutics, where he was Chief Operating Officer.

Prior to joining Flagship in 2015, Jason was a core member of the Boston Consulting Group’s Health Care and Technology practices, operating out of BCG's New York, Mumbai, and Paris offices. His projects included several large life science M&A opportunities, and the design and implementation of a new funding model for a multinational global health organization focused on investing in innovative technologies and interventions. Previously, Jason was a director at an early-stage biotech start-up focused on targeted drug delivery as well as the co-founder of an internet advertising firm.

Jason earned a Ph.D., M.S., and B.S. in Biomedical Engineering from Yale University where his research focused on the use of nanotechnology for immunomodulatory purposes and culminated in the invention and clinical use of a nanoparticle drug delivery platform. He is the author of multiple patents, book chapters, and over a dozen peer-reviewed papers in journals including Nature and Cell.